166 related articles for article (PubMed ID: 33908324)
1. Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type.
Lucijanić M; Korunić RH; Sedinić M; Kušec R; Pejša V
Leuk Lymphoma; 2021 Oct; 62(10):2535-2538. PubMed ID: 33908324
[No Abstract] [Full Text] [Related]
2. [Low psoas muscle index as independent poor prognostic factor for diffuse large B-cell lymphoma in elderly patients].
Arai K; Mitsuhashi K; Honjo Y; Kurachi M; Komiya Y; Arao T; Sato H
Rinsho Ketsueki; 2022; 63(1):7-13. PubMed ID: 35135956
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era.
Liang X; Hu R; Li Q; Wang C; Liu Y
Exp Hematol; 2023 Jun; 122():1-9. PubMed ID: 36933759
[No Abstract] [Full Text] [Related]
5. Prognostic impact of the psoas muscle index, a parameter of sarcopenia, in patients with diffuse large B-cell lymphoma treated with rituximab-based chemoimmunotherapy.
Iltar U; Sözel H; Sözel YK; Ataş Ü; Yücel OK; Salim O; Aydin F; Undar L
Leuk Lymphoma; 2021 May; 62(5):1098-1106. PubMed ID: 33300380
[TBL] [Abstract][Full Text] [Related]
6. R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma.
Zhao F; Qin Y; Yang J; Liu P; He X; Zhou L; Zhou S; Gui L; Zhang H; Wang X; Jiang S; Zhong Q; Zhou Y; Shi Y
Asia Pac J Clin Oncol; 2020 Dec; 16(6):385-391. PubMed ID: 32779387
[TBL] [Abstract][Full Text] [Related]
7. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
Coiffier B; Salles G
Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
[No Abstract] [Full Text] [Related]
8. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T
Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
[No Abstract] [Full Text] [Related]
9. The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.
Długosz-Danecka M; Szmit S; Ogórka T; Skotnicki AB; Jurczak W
Cancer Med; 2019 Mar; 8(3):1103-1109. PubMed ID: 30740919
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.
Rier HN; Kharagjitsing H; van Rosmalen J; van Vugt J; Westerweel PE; de Jongh E; Kock M; Levin MD
Leuk Lymphoma; 2020 Jul; 61(7):1618-1626. PubMed ID: 32167390
[TBL] [Abstract][Full Text] [Related]
11. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
12. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
[TBL] [Abstract][Full Text] [Related]
13. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
14. Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
Kojima M; Amaki J; Ogiya D; Ando K; Nakamura N
J Clin Exp Hematop; 2020 Jun; 60(2):60-61. PubMed ID: 32404573
[No Abstract] [Full Text] [Related]
15. DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.
Shimazu Y; Nohgawa M
J Clin Exp Hematop; 2019; 59(2):93-95. PubMed ID: 31257349
[No Abstract] [Full Text] [Related]
16. Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.
Kari EJM; Kuusisto MEL; Honkavaara P; Hakalahti A; Haapasaari KM; Bloigu R; Karihtala P; Teppo HR; Pirinen R; Turpeenniemi-Hujanen T; Kuittinen O
Eur J Haematol; 2020 Aug; 105(2):156-163. PubMed ID: 32248578
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.
Nyman H; Adde M; Karjalainen-Lindsberg ML; Taskinen M; Berglund M; Amini RM; Blomqvist C; Enblad G; Leppä S
Blood; 2007 Jun; 109(11):4930-5. PubMed ID: 17299093
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
20. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
